Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from HeraMED Ltd. ( (AU:HMD) ).
HeraMED has reported a pivotal March 2026 quarter marked by advancing its U.S. commercial push for the HeraCARE platform through a deepening partnership with Philips and a promising pilot with Florida-based Lee Health. The company is transitioning from framework development to active joint sales with Philips into U.S. hospital systems, while the Lee Health phase 1 deployment has shown strong patient satisfaction and adherence, underpinning plans to scale from an initial cohort toward thousands of pregnancies.
The HeraCARE platform is gaining clinical scale, with 4,456 registered mothers and more than 200,000 recorded maternal vital measurements, strengthening HeraMED’s data-as-an-asset strategy aimed at improving outcomes and embedding the platform at enterprise level. Supported by a recent A$3.2 million capital raise, a lean cost base with quarterly cash outflow of A$851,000, and A$3.145 million cash on hand, HeraMED enters the current quarter with a solid balance sheet, an expanded U.S. commercial advisory capability, and clear foundations for broader adoption across the U.S. health system.
More about HeraMED Ltd.
HeraMED Ltd. is an ASX-listed medical data and technology company focused on the digital transformation of women’s and maternity care. Its core HeraCARE platform enables remote monitoring of pregnant women, collecting maternal vital signs and leveraging data and AI to support clinical workflows for hospitals, with a strategic emphasis on the U.S. healthcare market.
YTD Price Performance: 33.33%
Average Trading Volume: 1,622,548
Technical Sentiment Signal: Buy
Current Market Cap: A$53.13M
For detailed information about HMD stock, go to TipRanks’ Stock Analysis page.